CANNAPHARMARX, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | $324.1K | — | — | — |
| SG&A Expense | $8.8K | $6.6K | $276.8K | $4.2M | $425.5K | $80.3K | $89.6K | $97.1K |
| Operating Income | $-954.3K | $-6.6K | $-1.0M | $-11.7M | $-4.0M | $-80.3K | $-89.6K | $-97.1K |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $2.1M | $0 | $423 | $2.7K | $5.0K | — | — | — |
| Pretax Income | $-3.1M | $-6.6K | $-1.0M | $-11.7M | $-4.0M | $-94.4K | $-98.1K | $-99.7K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Net Income | $-3.1M | $-6.6K | $-1.0M | $-11.7M | $-4.0M | $-94.4K | $-98.1K | $-99.7K |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.03 | $0.00 | $-0.01 | $-0.13 | $-0.06 | $-0.01 | $-0.01 | $-0.01 |
| EPS (Diluted) | $-0.03 | $0.00 | $-0.01 | $-0.13 | $-0.06 | $-0.01 | $-0.01 | $-0.01 |
| Shares Outstanding (Basic) | — | — | — | — | — | 14.3M | 14.3M | 14.3M |
| Shares Outstanding (Diluted) | 107.8M | 107.8M | 107.8M | 92.0M | 66.4M | 14.3M | 14.3M | 14.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |